Literature DB >> 17824920

Case report of HbC/beta(0)-thalassemia from India.

S Kumar1, M Rana, A Handoo, R Saxena, I C Verma, M Bhargava, S K Sood.   

Abstract

This 22-year-old women presented to the ante-natal clinic of this hospital for prenatal screening for beta-thalassemia. Cation exchange high performance liquid chromatography (HPLC) using 'Beta Thalassemia Short Program' on Bio-Rad 'Variant' system revealed HbC value of 81.6%. The CBC showed microcytic hypochromic anemia. The HPLC and CBC suggested the possibility of compound heterozygote state for HbC/beta-thalassemia. The alkali and acid electrophoresis findings were consistent with the above diagnosis. The DNA analysis confirmed compound heterozygote state for HbC/beta(0)-thalassemia (Fr 8/9 mutation). The studies on the parents showed that mother was a compound heterozygote for HbD(Punjab) and HbC while father had beta-thalassemia trait. To the best of our knowledge, this is the first confirmed report of HbC from India. The paper discusses the hematological findings in this subject and her mother (a compound heterozygote for HbD(Punjab) and HbC).

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17824920     DOI: 10.1111/j.1365-2257.2006.00850.x

Source DB:  PubMed          Journal:  Int J Lab Hematol        ISSN: 1751-5521            Impact factor:   2.877


  3 in total

1.  Utility of family studies in diagnosing abnormal hemoglobins/thalassemic states.

Authors:  Aruna Rangan; A Handoo; S Sinha; R Saxena; I C Verma; S Kumar; S K Sood; M Bhargava
Journal:  Indian J Pediatr       Date:  2009-04-23       Impact factor: 1.967

2.  C-Window Peaks on CE-HPLC are Extremely Rare in Northern India, and Only Infrequently Represent HbC.

Authors:  Jasmita Dass; Suchi Mittal; Amrita Saraf; Jyoti Kotwal
Journal:  Indian J Hematol Blood Transfus       Date:  2017-04-09       Impact factor: 0.900

Review 3.  Past, present & future scenario of thalassaemic care & control in India.

Authors:  Ishwar C Verma; Renu Saxena; Sudha Kohli
Journal:  Indian J Med Res       Date:  2011-10       Impact factor: 2.375

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.